Candidate Surrogate End Points for ESRD after AKI

AKI, a frequently transient condition, is not accepted by the US Food and Drug Association as an end point for drug registration trials. We assessed whether an intermediate-term change in eGFR after AKI has a sufficiently strong relationship with subsequent ESRD to serve as an alternative end point...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:J Am Soc Nephrol
Main Authors: Grams, Morgan E., Sang, Yingying, Coresh, Josef, Ballew, Shoshana H., Matsushita, Kunihiro, Levey, Andrew S., Greene, Tom H., Molnar, Miklos Z., Szabo, Zoltan, Kalantar-Zadeh, Kamyar, Kovesdy, Csaba P.
Format: Artigo
Jezik:Inglês
Izdano: American Society of Nephrology 2016
Teme:
Clinical Epidemiology
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5004655/
https://ncbi.nlm.nih.gov/pubmed/26857682
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1681/ASN.2015070829
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki